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Preventing thrombotic complications in cancer patients is
highly relevant above-and-beyond IST. New approaches in cancer
patients have been investigated and the hypothesis that strategies
to inhibit clotting mechanism may favorably affect malignant
disease is gaining interest. Evidence-based strategies are being
developed to treat cancer patients with venous thromboembolism.
Phenprocoumon (warfarin and derivates) is problematic in cancer
patients because of unpredictable responses and variable efficacy.
Hull et al. (11) recently reported a multicenter, randomized,
open-label clinical trial using objective outcome measures compar-
ing long-term therapeutic low molecular weight heparin subcuta-
neously to warfarin therapy in cancer patients. Bleeding compli-
cations were the same. However, 16% of the warfarin group
developed thrombosis recurrence, compared with 7% in the low-
molecular-weight heparin group.
We are uncertain how stented cancer patients should be best
treated. Five of 6 developed IST despite optimal antiplatelet
therapy. Whether or not these patients should receive subcutane-
ous low molecular weight heparin, as did the cancer patients in the
trial by Hull et al. (11), is unknown. We pose the question of how
cancer patients will respond to drug-eluting stents. These stents
behave differently to endothelial repair. We have not placed such
stents in cancer patients. Consideration could also be given to treat
such high-risk patients with balloon dilatation alone without
stenting. Surveillance studies are necessary to address this impor-
tant question.
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Letters to the Editor
Debating About a Registry
to Define the Best Invasive
Treatment for Obstructive
Hypertrophic Cardiomyopathy
Should It Also Include
Obstructive Patients Medically Treated?
We have read with great interest the Viewpoint by Olivotto et al.
(1) that recently was published in the Journal. The authors have
convincingly demonstrated that a randomized prospective trial
comparing the results of these 2 techniques is not feasible, because
it would require the enrollment of more than 30,000 patients with
hypertrophic cardiomyopathy. We agree with their conclusion that
this issue can only be addressed by a large international multicenter
registry.
However, in our opinion, the discussion on the respective
advantages of surgical myectomy and alcohol septal ablation should
not distract from the crucial and, still controversial, question of
which patients are appropriate candidates for the myectomy
operation. Indeed, the international guidelines on hypertrophic
cardiomyopathy define candidates to myectomy as “both adults
and children with obstructive hypertrophic cardiomyopathy and
severe drug-refractory symptoms” (2). On the other hand, 2 recent
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retrospective studies performed in centers with a particularly large
experience with the myectomy operation have shown that survival
in patients with obstructive hypertrophic cardiomyopathy and
heart failure symptoms who underwent myectomy is similar to that
of patients with the nonobstructive form of the disease, and
substantially more favorable than that of nonoperated obstructive
patients (3,4). Both studies raise the important question of
whether young patients with obstructive hypertrophic cardiomy-
opathy, a marked outflow gradient, and a dilated left atrium should
be operated earlier, without waiting for the development of severe
symptoms of heart failure unresponsive to medical treatment. On
the basis of these recent results, cardiac surgeons with a large
experience and very low operative mortality for the myectomy
operation are now confronted with the dilemma of whether to
operate young patients with outflow obstruction earlier in their
clinical course, without waiting for progression to severe heart
failure symptoms.
Therefore, we would like to take this opportunity to stress the
need for a large international multicenter registry of the clinical
course and management of patients with the obstructive form of
hypertrophic cardiomyopathy, focused not only on the comparison
of the results of myectomy operation versus alcohol septal ablation,
but also on the selection of the proper candidates to surgery.
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Reply
We are grateful to Dr. Ferrazzi and colleagues for their thoughtful
comments and interest in our work (1). The primary issue raised in
their letter is indeed an important one; should surgical septal
myectomy for obstructive hypertrophic cardiomyopathy (HCM)
be offered to patients with less than severe drug-refractory symp-
toms, instead of waiting for the progression to New York Heart
Association (NYHA) functional class III to IV? At this time,
however, we believe that there is no compelling evidence to allow
for such radical liberalization of the established selection criteria
for surgical septal myectomy (or alcohol septal ablation) (2).
For example: 1) Patients with NYHA functional class III to IV
symptoms of heart failure improve measurably after myectomy,
often achieving functional class I (2–4). Obviously, symptomatic
improvement cannot represent a clinical target in NYHA func-
tional class I to II patients. 2) Postoperatively, patients with class
III to IV symptoms have a long-term survival benefit equivalent to
that of the general population (4). 3) There are few (if any)
available data documenting irreversible heart failure despite ade-
quate myectomy, due to an excessive period of NYHA functional
class III to IV symptoms. 4) No consistent data support the
advantage of myectomy in reducing left atrial size and the
propensity for atrial fibrillation (2,5). For example, in the paper by
Woo et al. (3), a substantial proportion of operated patients still
went on to develop atrial fibrillation during follow-up.
On the other hand, we agree with Dr. Ferrazzi and colleagues
that is probably not necessary or advisable to require symptomatic
patients with obstructive HCM to prolong decisions regarding
operative intervention until they are essentially disabled. Indeed,
once symptoms related to obstruction become fixed and unrespon-
sive to conventional pharmacologic treatment, further medical
treatment is unlikely to result in clinical improvement equivalent to
that expected following myectomy.
Finally, it is tantalizing to consider earlier intervention with surgical
myectomy, given the very low operative mortality now reported by
major centers (4). Nevertheless, we hesitate to promote myectomy for
asymptomatic or mildly symptomatic patients with obstructive HCM,
given that open-heart procedures are never without a mortality and
morbidity risk, even at particularly experienced centers (2,4,5).
Therefore, we welcome the suggestion of expanding the multi-
center registry for obstructive HCM that we have proposed, as a
tool to identify ideal candidates for septal reduction therapies (1).
However, such registry may ultimately prove of limited value in
establishing the need for earlier intervention in HCM patients.
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